Clinical phase II, multicenter, open trabectedin (Yondelis ®) in patients with advanced breast cancer, HER2 negative, hormone receptor-positive, with gene overexpression or subexpression class xeroderma pigmentosum G (XPG).

Trial Profile

Clinical phase II, multicenter, open trabectedin (Yondelis ®) in patients with advanced breast cancer, HER2 negative, hormone receptor-positive, with gene overexpression or subexpression class xeroderma pigmentosum G (XPG).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Oct 2011 EudraCT identified as an additional source and identifiers, multiple endpoints and patient inclusion/exclusion criteria added
    • 17 Oct 2011 Planned number of patients changed from 40 to 100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top